| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01472055 | Acute Leukemia|Chronic Leukemia|Severe Aplastic Anemia | Drug: Fludarabine | Seoul National University Hospital|Ministry of Food and Drug Safety, Korea | Phase 2 | 2011-10-01 | 2014-08-18 |
| NCT01310179 | Head and Neck Cancer | Genetic: Ad/PNP and fludarabine monophosphate | PNP Therapeutics, Inc. | Phase 1 | 2011-02-01 | 2015-05-26 |
| NCT02649764 | Leukemia | Drug: Fludarabine|Drug: Cytarabine|Drug: LY2606368 | M.D. Anderson Cancer Center|Eli Lilly and Company | Phase 1 | 2016-05-01 | 2017-02-16 |
| NCT00004246 | Head and Neck Cancer | Drug: Fludarabine Phosphate|Radiation: Radiation Therapy (RT) | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Phase 1 | 2000-05-01 | 2012-07-27 |
| NCT00208975 | Lymphoma | Drug: Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF | Emory University|Bayer | Phase 2 | 2002-07-01 | 2012-05-25 |
| NCT02718755 | Hematologic Malignancy | Drug: Fludarabine|Drug: Cytarabine|Drug: Erwinase | M.D. Anderson Cancer Center|Jazz Pharmaceuticals | Phase 2 | 2016-12-01 | 2016-09-19 |
| NCT00278265 | T-Cell Large Granular Lymphocytic Leukemia | Drug: MTX followed by fludarabine | German CLL Study Group | Phase 2 | 2005-06-01 | 2016-09-30 |
| NCT00086580 | B-Cell Chronic Lymphocytic Leukemia | Biological: FluCAM [Fludara + Campath]|Biological: fludarabine phosphate | Genzyme, a Sanofi Company|Sanofi | Phase 3 | 2004-07-01 | 2014-02-10 |
| NCT01096992 | Leukemia | Drug: Bendamustine|Drug: Fludarabine|Drug: Rituximab | M.D. Anderson Cancer Center | Phase 1|Phase 2 | 2010-04-01 | 2016-08-17 |
| NCT00098670 | B-cell Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia | Biological: alemtuzumab|Biological: rituximab|Drug: fludarabine phosphate | National Cancer Institute (NCI) | Phase 2 | 2004-10-01 | 2014-05-06 |
| NCT00502905 | Leukemia | Drug: Busulfan|Drug: Fludarabine | M.D. Anderson Cancer Center | Phase 2 | 2003-10-01 | 2012-05-23 |
| NCT02926586 | Acute Myeloid Leukemia|Core-Binding Factor | Drug: Fludarabine|Drug: Cytarabine | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 4 | 2016-07-01 | 2016-10-05 |
| NCT00185445 | Non Hodgkin Lymphoma | Drug: Fludarabine Phosphate (Fludara) | Genzyme, a Sanofi Company|Sanofi | Phase 2 | 2004-06-01 | 2013-12-02 |
| NCT00625430 | Prostate Cancer | Biological: Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine | Biotech Equity Partners Pty Ltd | Phase 1 | 2008-03-01 | 2011-07-08 |
| NCT00506857 | Hematologic Malignancies | Drug: Busulfan|Drug: Fludarabine | M.D. Anderson Cancer Center | Phase 1|Phase 2 | 2003-11-01 | 2012-01-24 |
| NCT00688883 | Lymphoma | Drug: Fludarabine Phosphate (Fludara) | Genzyme, a Sanofi Company|Sanofi | Phase 2 | 2003-02-01 | 2013-12-02 |
| NCT01019317 | Leukemia|AML|MDS|CML | Drug: Cytarabine|Drug: Fludarabine | M.D. Anderson Cancer Center | Phase 2 | 2009-11-01 | 2016-02-17 |
| NCT00006251 | Acute Undifferentiated Leukemia|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Juvenile Myelomonocytic Leukemia|Mast Cell Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myeloid/NK-cell Acute Leukemia|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Systemic Amyloidosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Renal Cell Cancer|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage II Multiple Myeloma|Stage III Multiple Myeloma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenstrm Macroglobulinemia | Radiation: total-body irradiation|Drug: fludarabine phosphate|Drug: cyclosporine|Drug: mycophenolate mofetil|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Biological: donor lymphocytes|Procedure: peripheral blood stem cell transplantation|Other: laboratory biomarker analysis | Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) | Phase 1|Phase 2 | 2000-05-01 | 2016-08-01 |
| NCT00815568 | AML|MDS|ALL|CML|Lymphoma | Drug: fludarabine phosphate, busulfan | Samsung Medical Center | Phase 2 | 2008-08-01 | 2008-12-29 |
| NCT00058227 | B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Progressive Hairy Cell Leukemia, Initial Treatment|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Splenic Marginal Zone Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Untreated Hairy Cell Leukemia|Waldenstr枚m Macroglobulinemia | Drug: alvocidib|Drug: fludarabine phosphate|Biological: rituximab|Other: pharmacological study | National Cancer Institute (NCI) | Phase 1 | 2003-04-01 | 2013-06-03 |
| NCT00882323 | Aplastic Anemia | Drug: Cyclophosphamide, Fludarabine, Thymoglobulin | The Korean Society of Pediatric Hematology Oncology | Phase 2 | 2008-11-01 | 2012-03-23 |
